KEYTRUDA® Boosts Survival in High-Risk Locally Advanced Cervical Cancer
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has announced the successful outcome of the Phase 3 KEYNOTE-A18 trial, also recognized as ENGOT-cx11 This trial assessed KEYTRUDA, Merck’s anti-PD-1 therapy, combined with chemoradiotherapy (CRT) for…